Comparative Efficacy of Atorvastatin and Placebo in Intensive Care Unit Patients with Coronavirus Disease 2019: A Randomized Controlled Trial
Atorvastatin could effectively reduce inflammation in intensive care unit (ICU) patients admitted for COVID-19 management, but it could not influence the clinical outcomes. We suggested investigating its effect on COVID-19 in larger sample sizes, nonICU patients, and from the beginning of the diagnosis for a longer duration.
Authors
- Fatemeh Taghavi
- Saeed Abbasi (ORCID: https://orcid.org/0000-0003-0930-5698)
- Shadi Farsaei (ORCID: https://orcid.org/0000-0002-8189-6384)
- Malihe Nejati
Institutions
- Isfahan University of Medical Sciences (IR)
- Birjand University of Medical Sciences (IR)
Publication Details
- Journal
- Journal of Research in Pharmacy Practice
- Published
- 2024-10-01
- DOI
- https://doi.org/10.4103/jrpp.jrpp_10_25
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00